title: [Experimental study on treating hyperlipidemic fatty liver with Taizhi'an capsule].
abstract: OBJECTIVE
  To observe the effects of Taizhi'an capsule in treatment of hyperlipidemic fatty liver.
  
  
  METHODS
  The model rats were induced by feeding high caloric diet for 8 weeks, then fifty rats were randomly divided into five groups, and each group had ten rats, the Taizhi'an groups (high dose 1 000 mg x kg(-1), middle dose 500 mg x kg(-1), low dose 250 mg x kg(-1)), the Yishanfu group and the model group. Liver index (liver weight/body weight), liver function, blood lipid, liver lipid, the content of MDA and SOD in liver were assayed after therapy, and observe Pathologic changes in rats liver.
  
  
  RESULTS
  Liver index, blood lipid, liver lipid, liver function increased significantly (P < 0.001) in model rats, and the content of SOD in liver decreased significantly (P < 0.05), Liver histology expressed mild to moderate fat denaturation; After being treated with high and middle dose of Taizhi'an capsule for six weeks, blood lipid, liver function decreased significantly (P < 0.001), and liver lipid decreased significantly (P < 0.001, P <0.05), the content of SOD in liver increased significantly (P < 0.05), meanwhile liver histology was closed to normal.
  
  
  CONCLUSIONS
  Taizhian capsule is effective in the treatment of hyperlipidemic induced fatty liver.
authors.affiliation: Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou 310009, China.
authors.forename: Mei
authors.initials: M
authors.lastname: Sun
authors.forename: Jian-Zhen
authors.initials: JZ
authors.lastname: Shan
authors.forename: Guo-Ping
authors.initials: GP
authors.lastname: Zhang
authors.forename: Hua-Zhong
authors.initials: HZ
authors.lastname: Ying
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D002214:Capsules; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000494:pharmacology*; D005234:Fatty Liver / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D006949:Hyperlipidemias / Q000150:complications; D031659:Ligustrum / Q000737:chemistry; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008517:Phytotherapy; D018515:Plant Leaves / Q000737:chemistry; D010946:Plants, Medicinal / Q000737:chemistry; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013482:Superoxide Dismutase / Q000378:metabolism; D014280:Triglycerides / Q000097:blood / Q000378:metabolism; D014315:Triterpenes / Q000008:administration & dosage / Q000494:pharmacology; D000097245:Ursolic Acid
chemical_list: D000410:Alanine Transaminase; D001219:Aspartate Aminotransferases; D002214:Capsules; D002784:Cholesterol; D004365:Drugs, Chinese Herbal; D008315:Malondialdehyde; D013482:Superoxide Dismutase; D014280:Triglycerides; D014315:Triterpenes; D000097245:Ursolic Acid; C513940:taizhi'an